QR kód

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions

Dabigatran, rivaroxaban, apixaban, and edoxaban are direct oral anticoagulants (DOACs) that are increasingly used worldwide. Taking into account their widespread use for the prevention of thromboembolism in cardiology, neurology, orthopedics, and coronavirus disease 2019 (COVID 19) as well as their...

Celý popis

Uloženo v:
Hlavní autoři: Natalia A. Shnayder, Marina M. Petrova, Pavel A. Shesternya, Alina V. Savinova, Elena N. Bochanova, Olga V. Zimnitskaya, Elena A. Pozhilenkova, Regina F. Nasyrova
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI AG 2021-04-01
Edice:Biomedicines
Témata:
pharmacokinetics
pharmacogenetics
dabigatran
rivaroxaban
apixaban
edoxaban
On-line přístup:https://www.mdpi.com/2227-9059/9/5/451
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky